CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using ...

Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE)-- ...

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...

New RNA-based algorithm is now available with the xR assay “This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep ...

Nodal involvement and impact of adequate staging in older patients with resectable colon cancer: A population-based analysis. Targeted analysis of progressive metabolic perturbations in colorectal ...

Boston Cell Standards today announced the publication of the CASI-01 study in Lancet: eBioMedicinedemonstrating that calibration dramatically improves the accuracy and reproducibility of ...

Abdul Rafeh Naqash, M.D., is an assistant professor of medicine in the University of Oklahoma College of Medicine and research member of the OU Health Stephenson Cancer Center. Not all cancer ...

Metastatic castration-resistant prostate cancer (CRPC) is the lethal form of the disease. Many groups have performed mutational or immunohistochemistry (IHC) testing in metastatic CRPC to identify ...

The external assessment group (EAG) did a systematic review to identify evidence on the clinical effectiveness and diagnostic accuracy of IHC- and MSI-based testing strategies for detecting Lynch ...